IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific & Clinical Advisors
    • Partnerships
  • The DPX Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • DPX-Survivac
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Careers
    • Overview
    • Life at IMV
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Mar 01, 2021 7:05am EST

IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

Jan 04, 2021 7:05am EST

IMV to Participate in Two Upcoming Investor Events

Dec 28, 2020 7:05am EST

IMV Reports Update on COVID-19 Vaccine Program

Dec 06, 2020 8:15am EST

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

Dec 03, 2020 7:10am EST

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

Nov 13, 2020 7:05am EST

IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

Nov 12, 2020 7:05am EST

IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Nov 10, 2020 7:05am EST

IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer

Nov 09, 2020 5:05pm EST

IMV to Participate in Two Upcoming Investor Conferences

Nov 09, 2020 8:00am EST

IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...35
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us The DPX Platform Clinical Pipeline News & Events Investors Careers Contact
Twitter LinkedIn Youtube
© 2021 IMV Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap